Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enpro Inc.NPO · Entity 3782 | Director | September 16, 2026 | September 17, 2026 |
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | Director | January 07, 2026 | January 10, 2026 |
| Tyra Biosciences, Inc.TYRA · Entity 4680 | Director | May 28, 2026 | June 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enpro Inc.
Report date September 16, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security | Direct | 5,281.7774 |
Reported balance
After 2026-09-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-16 · Grant · Acquired 5 · Balance 5,281.7774 F1: 1-for-1 F2: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. |
| Phantom StockSEC Table II · derivative / convertible security | Direct | 5,282.351 |
Reported balance
After 2026-09-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-16 · Grant · Acquired 0.5736 · Balance 5,282.351 F1: 1-for-1 F5: Dividend equivalent rights accrued to previously acquired phantom stock under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc. F3: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F4: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. |
Filing footnotes · ownership attribution and instrument terms
F1: 1-for-1
F2: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc.
F3: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate.
F4: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents.
F5: Dividend equivalent rights accrued to previously acquired phantom stock under the Deferred Compensation Plan for Non-Employee Directors (as amended and restated) of EnPro Industries, Inc.
NewAmsterdam Pharma Co N.V.
Report date January 07, 2026 · Filed January 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 14,260 |
Reported balance
After 2026-01-07 transaction · row 1
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 3,400 · Balance 14,260 F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. F2: Each RSU was granted on January 7, 2026 for no consideration. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.45 · Expires 2036-01-07 | Direct | 15,300 |
Reported balance
After 2026-01-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-07 · Grant · Acquired 15,300 · Balance 15,300 F3: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
F2: Each RSU was granted on January 7, 2026 for no consideration.
F3: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
Tyra Biosciences, Inc.
Report date May 28, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.68 · Expires 2036-05-27 | Direct | 13,160 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 13,160 · Balance 13,160 F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BEMIS CO INC
Report date June 11, 2019 · Filed June 11, 2019
Section 16 reporting ended · disclosed 2019-06-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-06-11 transaction · row 1
1 source rowRow 1 · 2019-06-11 · Disposition to issuer · Disposed 12,383 · Balance 0 F1: Disposed of as a result of merger pursuant to the previously announced Transaction Agreement, dated as of August 6, 2018 (which, as it may be amended from time to time, we refer to as the "Transaction Agreement"), by and among Amcor plc (f/k/a Arctic Jersey Limited)("New Amcor"), Amcor Limited, Arctic Corp. and Bemis Company, Inc. F2: Includes 96 shares acquired pursuant to a dividend equivalent feature upon settlement of a restricted stock unit. F3: Each share of common stock was cancelled pursuant to the Transaction Agreement in exchange for the right to receive the consideration provided in the Transaction Agreement (i.e., 5.1 ordinary shares of New Amcor for each such share, subject to applicable tax withholding and with cash payable in lieu of any fractional shares). |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of as a result of merger pursuant to the previously announced Transaction Agreement, dated as of August 6, 2018 (which, as it may be amended from time to time, we refer to as the "Transaction Agreement"), by and among Amcor plc (f/k/a Arctic Jersey Limited)("New Amcor"), Amcor Limited, Arctic Corp. and Bemis Company, Inc.
F2: Includes 96 shares acquired pursuant to a dividend equivalent feature upon settlement of a restricted stock unit.
F3: Each share of common stock was cancelled pursuant to the Transaction Agreement in exchange for the right to receive the consideration provided in the Transaction Agreement (i.e., 5.1 ordinary shares of New Amcor for each such share, subject to applicable tax withholding and with cash payable in lieu of any fractional shares).
Myovant Sciences Ltd.
Report date March 10, 2023 · Filed March 10, 2023
Section 16 reporting ended · disclosed 2023-03-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 1
1 source rowRow 1 · 2023-03-10 · Disposition to issuer · Disposed 3,673 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F2: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time. F3: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration"). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.17 · Expires 2030-02-23 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-10 · Disposition to issuer · Disposed 45,000 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.47 · Expires 2030-09-14 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-10 · Disposition to issuer · Disposed 21,603 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.71 · Expires 2031-11-04 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-10 · Disposition to issuer · Disposed 21,096 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").
F2: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time.
F3: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration").
F4: These options are fully vested.
F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2021 Filed Feb 18, 2021 18:02 UTC | Enpro Inc. NPO · Entity 3782 | GrantCommon Stock | 1,432 | $76.82 | $110,006.24 |
DisclosureSEC source: 0001225208-21-002904 · doc4.xml · nonDerivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,507 F1 · kind: Shares acquired pursuant to the EnPro Industries, Inc. 2020 Equity Compensation Plan. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 18:39 UTC | Enpro Inc. NPO · Entity 3782 | GrantPhantom Stock · Derivative | 14 | $73.91 | $1,034.74 |
DisclosureSEC source: 0001225208-20-014865 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,883 Underlying: Common Stock · 14 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F4 · price: Price is based on the closing selling price of common stock pursuant to the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F5 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 18:08 UTC | Enpro Inc. NPO · Entity 3782 | GrantPhantom Stock · Derivative | 17 | $57.46 | $976.82 |
DisclosureSEC source: 0001225208-20-011680 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,869 Underlying: Common Stock · 17 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F4 · price: Price is based on the closing selling price of common stock pursuant to the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F5 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 20:14 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 21,603 | $0.00 Strike: $21.47 | $0.00 |
DisclosureSEC source: 0001209191-20-050878 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,603 Underlying: Common Shares · 21,603 shares Expires 2030-09-14 F1 · derivative.exercise_date: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) September 15, 2021, and (b) the date that is one day prior to the Issuer's 2021 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 17:51 UTC | Enpro Inc. NPO · Entity 3782 | GrantPhantom Stock · Derivative | 22 | $45.52 | $1,001.44 |
DisclosureSEC source: 0001225208-20-009105 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,852 Underlying: Common Stock · 22 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F4 · price: Price is based on the closing selling price of common stock pursuant to the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F5 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document |
| March 18, 2020 Filed Mar 19, 2020 15:47 UTC | Enpro Inc. NPO · Entity 3782 | GrantPhantom Stock · Derivative | 30 | $32.58 | $977.40 |
DisclosureSEC source: 0001225208-20-005395 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,830 Underlying: Common Stock · 30 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F4 · price: Price is based on the closing selling price of common stock pursuant to the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F5 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document |
| February 24, 2020 Filed Feb 24, 2020 23:38 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $11.17 | $0.00 |
DisclosureSEC source: 0001209191-20-012197 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-02-23 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option vest and become exercisable on February 24, 2021, with the balance of the shares vesting in eight equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 14:18 UTC | Enpro Inc. NPO · Entity 3782 | GrantPhantom Stock · Derivative | 1,799 | $61.14 | $109,990.86 |
DisclosureSEC source: 0001225208-20-002694 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,800 Underlying: Common Stock · 1,799 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · shares: Shares acquired under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Upon retirement F4 · derivative.expiration_date: These shares do not have an expiration date and they are exercisable upon retirement Read SEC document |
| December 18, 2019 Filed Dec 19, 2019 20:35 UTC | Enpro Inc. NPO · Entity 3782 | GrantPhantom Stock · Derivative | 7 | $67.44 | $472.08 |
DisclosureSEC source: 0001225208-19-015988 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,001 Underlying: Common Stock · 7 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F4 · price: Price is based on the closing selling price of common stock pursuant to the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F5 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document |
| September 18, 2019 Filed Sep 19, 2019 15:24 UTC | Enpro Inc. NPO · Entity 3782 | GrantPhantom Stock · Derivative | 7 | $69.22 | $484.54 |
DisclosureSEC source: 0001225208-19-012676 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,994 Underlying: Common Stock · 7 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F4 · price: Price is based on the closing selling price of common stock pursuant to the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F5 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 15:01 UTC | Enpro Inc. NPO · Entity 3782 | GrantPhantom Stock · Derivative | 8 | $63.87 | $510.96 |
DisclosureSEC source: 0001225208-19-009473 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,987 Underlying: Common Stock · 8 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F4 · price: Price is based on the closing selling price of common stock pursuant to the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F5 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document |
| June 11, 2019 Filed Jun 11, 2019 16:23 UTC | BEMIS CO INC BMS · Entity 156671 | Disposition to issuerCommon Stock | 12,383 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-007487 · edgar.xml · nonDerivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of as a result of merger pursuant to the previously announced Transaction Agreement, dated as of August 6, 2018 (which, as it may be amended from time to time, we refer to as the "Transaction Agreement"), by and among Amcor plc (f/k/a Arctic Jersey Limited)("New Amcor"), Amcor Limited, Arctic Corp. and Bemis Company, Inc. F2 · shares: Includes 96 shares acquired pursuant to a dividend equivalent feature upon settlement of a restricted stock unit. F3 · price: Each share of common stock was cancelled pursuant to the Transaction Agreement in exchange for the right to receive the consideration provided in the Transaction Agreement (i.e., 5.1 ordinary shares of New Amcor for each such share, subject to applicable tax withholding and with cash payable in lieu of any fractional shares). Read SEC document |
| March 20, 2019 Filed Mar 21, 2019 19:52 UTC | Enpro Inc. NPO · Entity 3782 | GrantPhantom Stock · Derivative | 7 | $66.59 | $466.13 |
DisclosureSEC source: 0001225208-19-005648 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,979 Underlying: Common Stock · 7 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F4 · price: Price is based on the closing selling price of common stock pursuant to the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F5 · balance_after: Balance includes multiple phantom stock grants, phantom stock accruals and previously accrued dividend equivalents. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 17:19 UTC | Enpro Inc. NPO · Entity 3782 | PurchaseCommon Stock | 75 | $66.41 | $4,980.74 |
DisclosureSEC source: 0001225208-19-005707 · doc4.xml · nonDerivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75 Read SEC document |
| February 12, 2019 Filed Feb 13, 2019 19:54 UTC | Enpro Inc. NPO · Entity 3782 | GrantPhantom Stock · Derivative | 1,687 | $65.23 | $110,043.01 |
DisclosureSEC source: 0001225208-19-002415 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,972 Underlying: Common Stock · 1,687 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · shares: Shares acquired under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Upon retirement F4 · derivative.expiration_date: These shares do not have an expiration date and they are exercisable upon retirement Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 11:46 UTC | BEMIS CO INC BMS · Entity 156671 | GrantCommon Stock | 502 | $47.34 | $23,764.68 |
DisclosureSEC source: 0001179110-19-000735 · edgar.xml · nonDerivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,208 F1 · shares: Grant of Stock pursuant to the Reporting Person's election to receive her quarterly director compensation retainer payment in shares. Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 18:48 UTC | Enpro Inc. NPO · Entity 3782 | GrantPhantom Stock · Derivative | 1 | $59.08 | $59.08 |
DisclosureSEC source: 0001225208-18-016959 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285 Underlying: Common Stock · 1 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · kind: Dividend equivalent rights accrued to previously granted phantom stock awards under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F4 · price: Price is based on the closing selling price of common stock pursuant to the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. F3 · derivative.expiration_date: Vesting and payout occurs on the earliest of death, disability or the vesting and payout of the underlying award with respect to which the dividend equivalents relate. Read SEC document |
| October 30, 2018 Filed Oct 31, 2018 14:28 UTC | Enpro Inc. NPO · Entity 3782 | GrantPhantom Stock · Derivative | 284 | $57.83 | $16,423.72 |
DisclosureSEC source: 0001225208-18-014993 · doc4.xml · derivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284 Underlying: Common Stock · 284 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · shares: Shares acquired under the Amended and Restated 2002 Equity Compensation Plan of EnPro Industries, Inc. F3 · derivative.exercise_date: Upon retirement F4 · derivative.expiration_date: These shares do not have an expiration date and they are exercisable upon retirement Read SEC document |
| October 15, 2018 Filed Oct 16, 2018 10:45 UTC | BEMIS CO INC BMS · Entity 156671 | GrantCommon Stock | 523 | $45.45 | $23,770.35 |
DisclosureSEC source: 0001179110-18-012194 · edgar.xml · nonDerivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,706 F1 · shares: Grant of Stock pursuant to the Reporting Person's election to receive her quarterly director compensation retainer payment in shares. Read SEC document |
| July 16, 2018 Filed Jul 17, 2018 10:58 UTC | BEMIS CO INC BMS · Entity 156671 | GrantCommon Stock | 569 | $41.81 | $23,789.89 |
DisclosureSEC source: 0001179110-18-009716 · edgar.xml · nonDerivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,183 F1 · shares: Grant of Stock pursuant to the Reporting Person's election to receive her quarterly director compensation retainer payment in shares. Read SEC document |
| May 03, 2018 Filed May 4, 2018 13:52 UTC | BEMIS CO INC BMS · Entity 156671 | GrantCommon Stock | 3,095 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006242 · edgar.xml · nonDerivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,614 F1 · shares: Restricted stock unit granted to Bemis Director pursuant to 2014 Stock Incentive Plan exempt under Rule 16b-3: Grant made on May 3, 2018, as part of Director's Annual Fee, vests on the earlier of May 2, 2019 or 2019 annual meeting of shareholders. F2 · balance_after: Includes 77 shares acquired pursuant to a dividend equivalent feature upon settlement of a restricted stock unit. Read SEC document |
| April 16, 2018 Filed Apr 17, 2018 14:44 UTC | BEMIS CO INC BMS · Entity 156671 | GrantCommon Stock | 532 | $44.68 | $23,769.76 |
DisclosureSEC source: 0001179110-18-005703 · edgar.xml · nonDerivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,442 F1 · shares: Grant of stock pursuant to the Reporting Person's election to receive her quarterly director compensation retainer payment in shares. Read SEC document |
| May 04, 2017 Filed May 8, 2017 09:28 UTC | BEMIS CO INC BMS · Entity 156671 | GrantCommon Stock | 2,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-006759 · edgar.xml · nonDerivative · entry 1 Gulfo Adele M. · CIK 0001647102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,910 F1 · shares: Restricted stock unit granted to Bemis Director pursuant to 2014 Stock Incentive Plan exempt under Rule 16b-3: Grant made on May 4, 2017, as part of Director's Annual Fee, vests on the earlier of May 3, 2018 or 2018 annual meeting of shareholders. F2 · balance_after: Includes 47 shares acquired pursuant to a dividend equivalent feature upon settlement of a restricted stock unit. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.